Chemical inhibitors of protein kinases

被引：296

作者：

Bridges, AJ ^{[1
]}

机构：

[1] Ann Arbor Labs, Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA

来源：

CHEMICAL REVIEWS | 2001年 / 101卷 / 08期

关键词：

D O I：

10.1021/cr000250y

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The role of Protein kinases as potential drug tragets was studied. The use of protein kinases for cellular signaling and cancer therapy was discussed. The chemical inhibitors of protein kinases like PKC and BCR-ABL along with epidermal growth factor receptor TK inhibitors and anilinopyrimidine inhibitors were also described.

引用

页码：2541 / 2571

页数：31

共 259 条

[31]

BURGER AM, 1995, CANCER RES, V55, P2794

[32]

CACACE AM, 1993, ONCOGENE, V8, P2095

[33] Protein kinase C: A worthwhile target for anticancer drugs? [J].

Caponigro, F ;

French, RC ;

Kaye, SB .

ANTI-CANCER DRUGS, 1997, 8 (01) :26-33

[34] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].

Carroll, M ;

OhnoJones, S ;

Tamura, S ;

Buchdunger, E ;

Zimmermann, J ;

Lydon, NB ;

Gilliland, DG ;

Druker, BJ .

BLOOD, 1997, 90 (12) :4947-4952

[35] Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin [J].

Cassinelli, G ;

Lanzi, C ;

Pensa, T ;

Gambetta, RA ;

Nasini, G ;

Cuccuru, G ;

Cassinis, M ;

Pratesi, G ;

Polizzi, D ;

Tortoreto, M ;

Zunino, F .

BIOCHEMICAL PHARMACOLOGY, 2000, 59 (12) :1539-1547

[36] Biology of BCR-ABL [J].

Chopra, R ;

Pu, QQ ;

Elefanty, AG .

BLOOD REVIEWS, 1999, 13 (04) :211-229

[37]

Ciardiello F, 2000, CLIN CANCER RES, V6, P2053

[38]

CIARDIELLO F, 1999, P AACR NCI EORTC INT

[39]

COCKERILL GS, 2001, Patent No. 0104111

[40]

COCKERILL GS, 1997, Patent No. [09713771, 9713771]

← 1 2 3 4 5 6 7 8 9 10 →